1. Home
  2. CING vs SYBX Comparison

CING vs SYBX Comparison

Compare CING & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CING
  • SYBX
  • Stock Information
  • Founded
  • CING 2012
  • SYBX N/A
  • Country
  • CING United States
  • SYBX United States
  • Employees
  • CING N/A
  • SYBX N/A
  • Industry
  • CING Biotechnology: Pharmaceutical Preparations
  • SYBX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CING Health Care
  • SYBX Health Care
  • Exchange
  • CING Nasdaq
  • SYBX Nasdaq
  • Market Cap
  • CING 16.2M
  • SYBX 13.6M
  • IPO Year
  • CING 2021
  • SYBX N/A
  • Fundamental
  • Price
  • CING $4.36
  • SYBX $1.21
  • Analyst Decision
  • CING Strong Buy
  • SYBX
  • Analyst Count
  • CING 4
  • SYBX 0
  • Target Price
  • CING $30.67
  • SYBX N/A
  • AVG Volume (30 Days)
  • CING 250.6K
  • SYBX 12.2K
  • Earning Date
  • CING 05-08-2025
  • SYBX 06-17-2025
  • Dividend Yield
  • CING N/A
  • SYBX N/A
  • EPS Growth
  • CING N/A
  • SYBX N/A
  • EPS
  • CING N/A
  • SYBX 0.21
  • Revenue
  • CING N/A
  • SYBX N/A
  • Revenue This Year
  • CING N/A
  • SYBX N/A
  • Revenue Next Year
  • CING N/A
  • SYBX N/A
  • P/E Ratio
  • CING N/A
  • SYBX $5.82
  • Revenue Growth
  • CING N/A
  • SYBX N/A
  • 52 Week Low
  • CING $1.80
  • SYBX $0.90
  • 52 Week High
  • CING $20.83
  • SYBX $1.88
  • Technical
  • Relative Strength Index (RSI)
  • CING 61.94
  • SYBX 58.34
  • Support Level
  • CING $3.81
  • SYBX $1.00
  • Resistance Level
  • CING $4.09
  • SYBX $1.27
  • Average True Range (ATR)
  • CING 0.26
  • SYBX 0.04
  • MACD
  • CING 0.07
  • SYBX 0.01
  • Stochastic Oscillator
  • CING 96.43
  • SYBX 69.05

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Share on Social Networks: